Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ironwood Pharmaceuticals
Biotech
Ironwood seeing STARS as phase 3 hit triggers 30% stock drop
While the study met its primary endpoint, the results failed to convince investors it can win out over rivals such as Takeda’s Gattex.
Nick Paul Taylor
Feb 29, 2024 7:52am
Ironwood pays $1B for VectivBio and its phase 3 GI drug
May 22, 2023 10:05am
Tour de biotech: Cyclerion peddles through another disease area
Oct 6, 2022 10:30am
Ironwood starts pipeline rebuild with liver disease deal
Nov 4, 2021 8:40am
2020’s top 10 clinical trial flops
Jan 25, 2021 3:00am
Proxy brawler Denner joins board at Ironwood—Chutes & Ladders
Nov 13, 2020 10:20am